10 Einträge gefunden

1. Health-Related QOL Differs by Race/Ethnicity in North American Patients with Psoriasis: Results from PSOLAR

   1. Takeshita, Junko
   2. Augustin, Matthias
   3. de Jong, Elke M G J
   4. Lafferty, Kimberly Parnell
   5. Langholff, Wayne
   6. Langley, Richard G
   7. Menter, Alan

   2022 - Forschungsinformationssystem des UKE
2. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

   1. Blauvelt, Andrew
   2. Armstrong, April W
   3. Langley, Richard G
   4. Gebauer, Kurt
   5. Thaçi, Diamant
   6. Bagel, Jerry
   7. Guenther, Lyn C

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

   1. Blauvelt, Andrew
   2. Langley, Richard G
   3. Lacour, Jean-Philippe
   4. Toth, Darryl
   5. Laquer, Vivian
   6. Beissert, Stefan
   7. Wollenberg, Andreas

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey

   1. Lebwohl, Mark
   2. Langley, Richard G
   3. Paul, Carle
   4. Puíg, Lluis
   5. Reich, Kristian
   6. van de Kerkhof, Peter
   7. Wu, Hsiuan-Lin

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis

   1. Langley, Richard G
   2. Poulin, Yves
   3. Srivastava, Bhaskar
   4. Lafferty, Kimberly Parnell
   5. Fakharzadeh, Steven
   6. Langholff, Wayne
   7. Augustin, Matthias

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

   1. Reich, Kristian
   2. Papp, Kim A
   3. Blauvelt, Andrew
   4. Langley, Richard G
   5. Armstrong, April
   6. Warren, Richard B
   7. Gordon, Kenneth B

   2021 - Forschungsinformationssystem des UKE
7. Bimekizumab versus Secukinumab in Plaque Psoriasis

   1. Reich, Kristian
   2. Warren, Richard B
   3. Lebwohl, Mark
   4. Gooderham, Melinda
   5. Strober, Bruce
   6. Langley, Richard G
   7. Paul, Carle

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
8. Bimekizumab versus Adalimumab in Plaque Psoriasis

   1. Warren, Richard B
   2. Blauvelt, Andrew
   3. Bagel, Jerry
   4. Papp, Kim A
   5. Yamauchi, Paul
   6. Armstrong, April
   7. Langley, Richard G

   2021 - Forschungsinformationssystem des UKE
9. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

   1. Reich, Kristian
   2. Armstrong, April W
   3. Langley, Richard G
   4. Flavin, Susan
   5. Randazzo, Bruce
   6. Li, Shu
   7. Hsu, Ming-Chun

   2019 - Forschungsinformationssystem des UKE
10. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2.

    1. Reich, Kristian
    2. Schenkel, Brad
    3. Zhao, Ning
    4. Szapary, Philippe
    5. Augustin, Matthias
    6. Bourcier, Marc
    7. Guenther, Lyn

    2011 - Forschungsinformationssystem des UKE